Mustang Bio to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities

Rhea-AI Summary

Mustang Bio, Inc. (NASDAQ: MBIO), a clinical-stage biopharmaceutical firm, announced its participation in the Fortress Biotech Virtual R&D Summit on April 5-6, 2022. Mustang’s management will present a corporate overview and join a panel discussion on April 6 at 1:30 p.m. ET. Interested parties can register for the event here. A webcast will be available for 30 days post-event on the Investor Relations section of Mustang’s website.

WORCESTER, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that members of Mustang’s management team will participate in the two-day Fortress Biotech (“Fortress”) Virtual R&D Summit taking place on Tuesday, April 5, 2022 and Wednesday, April 6, 2022. The Summit will be hosted by the B. Riley Securities’ Healthcare Equity Research team and will feature multiple programs from Fortress’ diversified pipeline.

Mustang will present a corporate overview and participate in a panel discussion on Wednesday, April 6, 2022 at 1:30 p.m. ET. Registration for the event is available here.

Following the meeting, the webcast will be available on the on the News & Events page of the Investor Relations section of Mustang’s website, www.mustangbio.com, for approximately 30 days after the meeting.

About Mustang Bio
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T therapies across multiple cancers, as well as lentiviral gene therapies for severe combined immunodeficiency. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). Mustang was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit www.mustangbio.com.

Forward‐Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing, including the effect of the current conflict in Europe; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Company Contacts:
Jaclyn Jaffe and Bill Begien
Mustang Bio, Inc.
(781) 652-4500
ir@mustangbio.com

Investor Relations Contact:
Daniel Ferry
LifeSci Advisors, LLC
(617) 430-7576
daniel@lifesciadvisors.com

Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com

FAQ

When is the Mustang Bio presentation at the Fortress Biotech Virtual R&D Summit?

Mustang Bio will present on April 6, 2022, at 1:30 p.m. ET.

How can I register for the Fortress Biotech Virtual R&D Summit?

Registration for the event is available here.

Where can I find the webcast after the Mustang Bio presentation?

The webcast will be available on Mustang's Investor Relations page for approximately 30 days after the event.

What is Mustang Bio's focus?

Mustang Bio focuses on cell and gene therapies for hematologic cancers, solid tumors, and rare genetic diseases.

Who is hosting the Fortress Biotech Virtual R&D Summit?

The Summit is hosted by the B. Riley Securities’ Healthcare Equity Research team.